Resource library - Median Technologies

Immunotherapies display novel response patterns that affect the design of imaging based studies and the subsequent evaluation of imaging data. Applying traditional chemotherapy-based response assumptions to immunotherapy trials can result in inaccurate interpretation of response, premature therapy termination, and unnecessary removal of subjects from a trial. Our unique solutions for medical image analysis and management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy.

Danny Francis [1], Vladimir Groza [1], Benoit Huet [1], Nozha Boujemaa [1] – Affiliations: [1] Median Technologies, Valbonne, France.

This work presents an end-to-end trained method and its preliminary results demonstrating the possibility to predict Overall Survival (OS) time for patients with lung cancer.